EUVIMEDFaigh amach EUVIMED
Open access

TACE Empowers Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors in Unresectable HCC: A Multicenter Retrospective Study

Yu Lei, Yaowei Bai, Xiatong Bai, Jiacheng Liu, Bo Sun, Wenlong Wu, Xiaoling Zhi, Yang Su, Hongsen Zhang, Chuansheng Zheng

Journal of Cancer · 2025-06-12 · 16 (8) · 2750-2761

DOI: 10.7150/jca.112706 ↗

At a glance

Journal article in Journal of Cancer, published on 2025-06-12. Written by Yu Lei and 9 co-authors. Institution: Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Cited 4 times so far (Crossref). The full text is freely available in PubMed Central.

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

Purpose

The aim of this multicenter retrospective study was to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) in treating advanced hepatocellular carcinoma (HCC) compared to treatment with TKI and ICI alone.

Methods

The study included 286 patients with advanced HCC, of which 210 were treated with TACE, TKI, and ICI (TACE+T+I group) and 76 with TKI and ICI alone (T+I group). Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and disease control rate (DCR) were assessed. A nomogram was developed to stratify patients into high-risk and low-risk groups based on their one-year and two-year survival probabilities.

Results

Patients in the TACE+T+I group demonstrated significantly longer PFS (8.4 months vs. 4.0 months, Log-rank P = 0.0016) and median OS (14.5 months vs. 10.0 months, Log-rank P < 0.0001) compared to the T+I group. Additionally, the TACE+T+I group had a higher ORR (56.7% vs. 21.1%, P = 0.002) and DCR (84.3% vs. 72.4%, P = 0.023). Both groups exhibited good tolerance to adverse events. A nomogram incorporating factors such as therapeutic strategy, prothrombin time (PT), age, and tumor size effectively categorized patients into low- and high-risk groups with notably different survival outcomes.

Conclusion

These findings suggest that TACE combined with TKI and ICI significantly improved survival outcomes and showed good safety compared to TKI and ICI alone in the treatment of advanced HCC.

Subjects

Author keywords

ICITKIcombination therapyhepatocellular carcinomatransarterial chemoembolization

Authors and institutions

  • Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430022, China.
  • Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.

Cite

APA

Lei, Y., Bai, Y., Bai, X., Liu, J., Sun, B., Wu, W., Zhi, X., Su, Y., Zhang, H., & Zheng, C. (2025). TACE Empowers Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors in Unresectable HCC: A Multicenter Retrospective Study. Journal of Cancer, 16(8), 2750-2761. https://doi.org/10.7150/jca.112706

Vancouver

Lei Y, Bai Y, Bai X, Liu J, Sun B, Wu W, et al. TACE Empowers Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors in Unresectable HCC: A Multicenter Retrospective Study. Journal of Cancer. 2025;16(8):2750-2761. doi:10.7150/jca.112706

BibTeX
@article{Lei2025,
  author = {Lei, Yu and Bai, Yaowei and Bai, Xiatong and Liu, Jiacheng and Sun, Bo and Wu, Wenlong and Zhi, Xiaoling and Su, Yang and Zhang, Hongsen and Zheng, Chuansheng},
  title = {TACE Empowers Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors in Unresectable HCC: A Multicenter Retrospective Study},
  journal = {Journal of Cancer},
  year = {2025},
  volume = {16},
  number = {8},
  pages = {2750--2761},
  doi = {10.7150/jca.112706}
}
Start for free →